Vivian Weiss, MD, PhD, has been named a 2020 V Scholar and will receive $200,000 from the V Foundation for Cancer Research.
News: Translational Research and Interventional Oncology Research Program
After a recent study showed that chronic lymphocytic leukemia patients who received ibrutinib as a frontline treatment had a 7% death rate, a new study offers a clearer picture on the reasons for the deaths.
Combining immunotherapy and radiation therapy may be a powerful treatment approach for castration-resistant prostate cancer.
Michael Savona, MD, professor of Medicine and Cancer Biology, and director of Hematology Research at Vanderbilt-Ingram Cancer Center, has received a competitive grant award from the Edward P. Evans Foundation.
Researchers are chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies.
The nature of childhood cancer is different than adult cancer, and so is the approach to treatment.
More than half of patients with relapsed multiple myeloma treated with carfilzomib experienced cardiac issues during treatment, according to a multi-institutional study published June 12 in the Journal of Clinical Oncology.
The U.S. Food and Drug Administration (FDA) recently approved ruxolitinib, the first drug for patients with acute graft-versus-host disease (GVHD) who have an inadequate response to steroid treatment.
Immunotherapy is helping cancer patient Roszell Mack Jr. to continue going to his job on a Kentucky horse farm.
Austin Kirschner, MD, PhD, and colleagues have studied the mechanism of radiation sensitization for enzalutamide using multiple models of human prostate cancer.